Short Interest in enGene Holdings Inc. (NASDAQ:ENGNW) Decreases By 27.5%

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a significant decline in short interest in January. As of January 30th, there was short interest totaling 1,115 shares, a decline of 27.5% from the January 15th total of 1,537 shares. Based on an average trading volume of 43,365 shares, the short-interest ratio is presently 0.0 days. Based on an average trading volume of 43,365 shares, the short-interest ratio is presently 0.0 days.

enGene Stock Performance

Shares of NASDAQ:ENGNW opened at $3.30 on Friday. enGene has a 52 week low of $0.51 and a 52 week high of $4.20. The company has a 50-day moving average price of $2.99 and a 200 day moving average price of $1.95.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.